Last reviewed · How we verify
NCT04807803: Evencipor
Evaluation of Minimal Hepatic Encephalopathy in Patients With Cirrhosis and Portal Hypertension
NA trial testing Assessment of Minimal hepatic encephalopathy (MHE) in Cirrhosis in 82 participants. Completed in 24 March 2025.
24 March 2025
Quick facts
| Lead sponsor | IHU Strasbourg |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 82 |
| Start date | 26 March 2021 |
| Primary completion | 24 March 2025 |
| Estimated completion | 24 March 2025 |
| Sites | 2 locations across France |
Drugs / interventions tested
- Assessment of Minimal hepatic encephalopathy (MHE)
Conditions studied
- Cirrhosis — all drugs for Cirrhosis →
- Portal Hypertension — all drugs for Portal Hypertension →
Sponsor
IHU Strasbourg — full company profile →
Who can join
18 and older, any sex, with Cirrhosis or Portal Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Minimal hepatic encephalopathy (MHE) is a subclinical cognitive impairment and represents the mildest type of hepatic encephalopathy (HE). Portal hypertension is the main complication of cirrhosis and is responsible of severe complications such as HE. The consequence of portal hypertension is the formation of the spontaneous portosystemic shunts (SPSS). The relationship between the SPSS and their characteristics and the prevalence of MHE in patient with cirrhosis is poorly known. The main objective of this study is to evaluate the MHE in patients with cirrhosis and portal hypertension.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04807803
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cirrhosis
Currently open trials in the same condition.
- NCT07322237 — DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis · Phase 4 · recruiting
- NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
- NCT07461545 — Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS · NA · recruiting
- NCT07461532 — Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD · NA · recruiting
- NCT07462091 — Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection · NA · recruiting
Other IHU Strasbourg trials
Trials by the same sponsor.
- NCT06017427 — Evaluation of Patient Satisfaction During Treatment With Dupilumab in Severe and Recurrent Nasosinusal Polyposis Despite · terminated
- NCT05515705 — First-in-human Navigation Endoscopic Ultrasound (EUS) System Clinical Study · NA · terminated
- NCT05357729 — Safety and Performance Study of the MultiSense® Ambulatory Telemonitoring System for Non-critical Patient Management · NA · completed
- NCT04899739 — Intraoperative Endoscopic Ultrasound for Pancreatic Cancer · NA · completed
- NCT05044585 — Evaluation of RDS MultiSense® in Desaturation Analysis in Healthy Volunteers · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04807803 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IHU Strasbourg
- Last refreshed: 16 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04807803.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing